- The Company plans to work with the FDA to design a Phase 3 program in moderate-to-high systemic disease activity patients to begin in 2023, ahead of expectations - DUBLIN--(BUSINESS WIRE)--Horizon ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback